Analyst Ratings for BridgeBio Pharma (BBIO)
BBIO Rating Summary
BBIO Price Target Summary
- Highest: $157.00 (Barclays)
- Lowest: $81.00 (Oppenheimer)
- Average: $105.64
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$105.64 (+38%)
* Over Last 12-Mos
Rating Score: 8.9 / 10
Percentile Rank: 88%
Avg. $ Target:
$105.64 (+38%)
* Over Last 12-Mos
Rating Score: 8.9 / 10
Percentile Rank: 88%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/3/2026 | Canaccord » Updated 8/12/2026 |
Whitney Ijem | New Coverage | Buy (N/A) |
106.00 (104.00) |
63.88 (76.57) |
19.87% | Details |
| 5/26/2026 | Raymond James | Martin Auster | Downgrade | Market Perform (Outperform) |
N/A (N/A) |
70.28 (76.57) |
8.95% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
